ASCO 2013 - Elizabeth A. Mittendorf, M.D., Ph.D., HER2 Peptide
Her2 vaccines are a step closer to getting in Standard of Care.
It will be awesome to have a vaccine to help prevent recurrence. I want to extend a special thanks to fellow Her2Support members who enrolled in vaccine trials.
For the newer board members, the trials are switching from Her2+++ to the lower expressors Her2+ and Her2++. These lower expressors are typically grouped into the "triple negative" category.
Phase II studies might still be open for us, the high expressors.
As we can see the numbers being offered be Dr. Mittendorf are based on the high expressors (us).
Personally I am hoping that the vaccines will eventually be approved for all patients with expressions of Her2, no matter what the level.
As Lani would put it, we want to keep the puppy in by closing the door (stop the growth of cancer by blocking a specific pathway).
Stage IIb Invasive Ductal Carcinoma, Pagets, 3 of 15 positive nodes
Traditional Treatment: Mastectomy and Axillary Node Dissection followed by Taxotere, 6 treatments and 1 year of Herceptin, no radiation
Former Chemo Ninja "Takizi Zukuchiri"
GP2 vaccine, San Antonio Med Ctr
Prescriptive Exercise for Cancer Patients
ENERGY Study, UCSD La Jolla
Reconstruction: TRAM flap, partial loss, Revision
The content of my posts are meant for informational purposes only. The medical information is intended for general information only and should not be used in any way to diagnose, treat, cure, or prevent disease
Last edited by 'lizbeth; 07-28-2013 at 10:33 AM..